Neuropore Therapies Inc., a biopharmaceutical company in San Diego, has launched Phase 1 clinical trials for its drug candidate NPT200-11, a potential treatment for Parkinson’s disease.
Dieter Meier, Neuropore’s CEO, said the company’s decision to progress into Phase 1 followed several years of very promising pre-clinical research.
In January 2015, Neuropore Therapies entered into a worldwide collaboration with Belgian drugmaker UCB to develop and commercialize NPT200-11.
To date, Neuropore has received $20.5 million of the potential $460 million in total milestones through its collaboration with UCB.
Neuropore is working on three drug discovery programs, all focusing on novel small molecule therapeutics to treat and slow the progression of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease.